Login to Your Account

Pharma: Other News To Note

Wednesday, October 9, 2013
• Medivir AB, of Stockholm, Sweden, said Janssen Pharmaceuticals Inc., a unit of New Brunswick, N.J.-based Johnson & Johnson, acquired investigational compound GSK2336805 (GSK805), an NS5a replication complex inhibitor in Phase II development of chronic hepatitis C virus (HCV) from an affiliate of London-based Glaxosmithkline plc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription